HLI98C is a HDM2 ubiquitin ligase inhibitor. HLI98C exhibits cytotoxic activities and HDM2 E3 ligase inhibitory activities. In cells, HLI98C allows the stabilization of p53 and HDM2 and activation of p53-dependent transcription and apoptosis. The p53 tumor suppressor protein is regulated by its interaction with HDM2, which serves as a ubiquitin ligase (E3) to target p53 for degradation. HLI98C may demonstrate anti-tumor activity by inhibiting recognition of the E3 enzyme and substrate. References: Dou X, Li X, Tao L, Hu C, Zhang L, He Q, Yang B, Hu Y. Synthesis and biological evaluation of novel pyrimido[4,5-b]quinoline-2,4- dione derivatives as MDM2 ubiquitin ligase inhibitors. Med Chem. 2013 Jun 1;9(4):581-7. PubMed PMID: 22920093.

纯度：≥98%

CAS：317326-90-2